Actively Recruiting
Treatment of Bile Acid Diarrhoea With Atorvastatin
Led by Asger Lund, MD · Updated on 2025-12-02
20
Participants Needed
1
Research Sites
58 weeks
Total Duration
On this page
Sponsors
A
Asger Lund, MD
Lead Sponsor
F
Fonden til Lægevidenskabens Fremme
Collaborating Sponsor
AI-Summary
What this Trial Is About
Bile acid diarrhoea (BAD) is a socially debilitating disease with stomach pain, high stool frequency, urgency, and faecal incontinence as the main symptoms. Studies estimate that 1-2% of the population suffers from the disease. There is an unmet need for more treatment options in patients suffering from BAD. The investigators hypothesise that atorvastatin treatment lowers bile acid synthesis in patients with bile acid diarrhoea. The investigators will investigate this hypothesis in the current study, BASTA, which is a Randomised, Double-Blind, Placebo-Controlled, Crossover, Proof of Concept, Investigator-Initiated, Trial.
CONDITIONS
Official Title
Treatment of Bile Acid Diarrhoea With Atorvastatin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- age 18 years or above
- Self-identification as White
- Confirmed moderate-severe bile acid diarrhoea with a SeHCAT test result of ≤ 10 %
- Reported number of average daily stools ≥ 3 stools per day
- Reported number of average daily watery (6 or 7 on the Bristol Stool Chart) stools ≥ 1 stools per day(30)
- Informed and written consent
You will not qualify if you...
- Unwillingness to pause any of the following medications during the trial: bile acid sequestrants, morphine medication, liraglutide or anti-constipation medication (e.g., lactulose, laxoberal, magnesia)
- Unwillingness to pause any anti-diarrhoea medication (e.g., imodium) from 3 days before initiation of each stool diary until after the respective visit
- If regularly administering psyllium or metformin, unwillingness to agree to a stable dose of psyllium or metformin throughout the trial
- Concomitant use of any drug in the GLP-1 receptor agonist drug class with the exception of paused liraglutide, see above
- Concomitant use of any kind of insulin medication
- Planned major changes in food consumption throughout the trial, including planned weight loss attempts
- Prior use of any statin within the recent 6 months
- Intake of larger quantities of grapefruit juice during trial participation, at the discretion of the investigator
- History of/present hepatobiliary disorder (except for simple metabolic dysfunction-associated fatty liver disease) and/or alanine aminotransferase and/or serum aspartate aminotransferase ≥ 3 times upper limit of normal
- Crohn's disease, ulcerative colitis, celiac disease or lactose intolerance
- Previous intestinal resection or major intra-abdominal surgery incl. stoma (cholecystectomy and appendectomy not included)
- Nephropathy with estimated glomerular filtration rate < 45 ml/min/1,73 m2
- Plasma level of creatine kinase ≥ 5 times the upper limit of normal
- A recent stroke or transient ischemic attack (within 6 months)
- Any treatment or condition requiring acute or subacute medical or surgical intervention
- Hypothyroidism or hyperthyroidism, if not well regulated, at the discretion of the investigator
- Active or recent (within 6 months) clinically significant malignant disease (non-melanoma skin cancer not included), at the discretion of the investigator
- Alcohol consumption exceeding 12 units/week for women or 18 units/week for men, respectively. These thresholds are based on the limits of the European Association for the Study of the Liver
- Drug abuse, at the discretion of the investigator
- Fertile women not using any of the following contraceptive methods for the duration of the trial until at least 5 days after end of trial: Hormonal (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormone intrauterine devices (IUD), hormonal vaginal ring or transdermal hormonal patch) associated with inhibition of ovulation, chemical (copper IUD), sterilisation, vasectomised partner with a confirmatory test, or sexual abstinence per the investigator's discretion
- Pregnant or nursing women
- Known or suspected hypersensitivity to atorvastatin or any of the additives in the tablet
- Receipt of any investigational drug within 30 days prior to visit 0
- Concomitant treatment with any of the following (topical administration not included): ciclosporin, telithromycin, clarithromycin, delavirdin, stiripentol, ketoconazol, voriconazol, itraconazol, posaconazol, letermovir, ritonavir, lopinavir, atazanavir, indinavir, darunavir, bocepravir, telaprevir, elbasvir/grazoprevir, ledipasvir/sofosbuvir, erythromycin, niacin, ezetimibe, fusidic acid, gemfibrozil, colchicine, digoxin, warfarin
- Unable to speak or understand Danish or mental incapacity that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements
- Active participation in any other clinical intervention trial (observational studies not included)
- Other concomitant disease or treatment that according to the investigator's assessment makes the person unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark, 2900
Actively Recruiting
Research Team
A
Asger B Lund, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here